Glaucoma News and Research

Latest Glaucoma News and Research

Researchers report game-changing advance in stem cell science

In a paper published in the April 25 early online edition of the Proceedings of the National Academy of Sciences, researchers at the University of California, San Diego School of Medicine, the Gladstone Institutes in San Francisco and colleagues report a game-changing advance in stem cell science: the creation of long-term, self-renewing, primitive neural precursor cells from human embryonic stem cells that can be directed to become many types of neuron without increased risk of tumor formation.

26 Apr 2011

UH honors glaucoma researcher with overall career excellence award

One of the world's foremost glaucoma researchers, Ronald S. Harwerth, is the recipient of the 2011 Esther Farfel Award, the highest distinction bestowed upon faculty by the University of Houston.

25 Apr 2011

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.

22 Apr 2011

Ortho-McNeil Neurologics announces voluntary recall of TOPAMAX 100mg Tablets

Ortho-McNeil Neurologics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., today announced it is voluntarily recalling two lots of TOPAMAX® (topiramate) 100mg Tablets. These two lots were shipped between 10/19/2010 and 12/28/2010 and distributed in the U.S. and Puerto Rico.

15 Apr 2011

Study: Patients with glaucoma experience psychological problems

Fear of the unknown is one of the greatest issues facing patients with glaucoma - the second leading cause of blindness worldwide after cataracts - according to research in the April issue of the Journal of Advanced Nursing. People also worry about how the eye disease, which can be hereditary, will affect other members of their family.

11 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

Optometrists congratulate Ontario government for progressive health policy

Ontarians will enjoy better access to eye health care now that optometrists can prescribe medications for sight-threatening conditions like eye infections and glaucoma.

7 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011

USPTO issues patent to Somaxon's Silenor food effect

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued U.S. patent no. 7,915,307, entitled "Methods of Improving the Pharmacokinetics of Doxepin."

30 Mar 2011

Diopsys launches new Vision Testing System to detect optic nerve disease

Diopsys, Inc. has launched the new Diopsys NOVA-DN VEP Vision Testing System to help optometrists and ophthalmologists detect optic nerve disease, including glaucoma and other neuro-visual disorders.

29 Mar 2011

Abbott launches Cataract Suite for micro-implantation procedure

Abbott announced today that it has introduced a Micro-Implantation Cataract Suite designed to help improve cataract procedure outcomes and safety.

29 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

NIH: Diabetic retinopathy leads to vision loss in working-age Americans

Diabetes is often called the "silent killer" because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people – including children – in the United States. Approximately one-quarter of those people do not know they're living with the disease.

23 Mar 2011

Astellas announces positive results from mirabegron phase III trials against OAB

Astellas Pharma Inc. today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder, show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.

23 Mar 2011

SMR, RTU enter license agreement for RESCULA eye drops

Sucampo Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Sucampo Manufacturing & Research AG, and R-Tech Ueno, Ltd., a pharmaceutical company founded in Japan in 1989, have entered into a license agreement for RESCULA eye drops, expanding Sucampo's rights beyond its previously agreed territory of the United States and Canada to all countries in Europe and the rest of the world except Japan, Korea, Taiwan and the People's Republic of China.

23 Mar 2011

Retina Implant to join with Wills Eye for U.S. artificial vision clinical trial

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced that they will partner with the Wills Eye Institute in Philadelphia as the lead U.S. clinical trial investigator site.

18 Mar 2011

FDA accepts Merck's SAFLUTAN NDA for standard review

Merck, known as MSD outside the United States and Canada, announced today that the New Drug Application for SAFLUTAN, Merck's investigational preservative-free prostaglandin analogue ophthalmic solution, has been accepted for standard review by the U.S. Food and Drug Administration.

10 Mar 2011

Aerie Pharmaceuticals closes $30 million Series B financing

Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing.

7 Mar 2011

Scientists discover SNPs linked with high risk of sick sinus syndrome

Scientists at deCODE genetics and academic colleagues from Iceland, The Netherlands, Denmark, USA and Illumina, Inc., today report the discovery of single-letter variants in the sequence of the human genome associated with high risk of sick sinus syndrome.

6 Mar 2011